Analysis of real-time PCR cycle threshold of α-thalassemia-1 southeast asian type deletion using fetal cell-free DNA in maternal plasma for noninvasive prenatal diagnosis of bart's hydrops fetalis

• Main Authors: Sakorn Pornprasert, Kanyakan Sukunthamala, Naowarat Kunyanone, Sririchai Sittiprasert, Khanungnit Thungkham, Sumeth Junorse, Khachonsilp Pongsawatkul, Wisut Pattanaporn, Chantip Jitwong, Torpong Sanguansermsri
• Format: Journal
• Published: 2018
• Subjects: Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=78649272558&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/51032
• Institution: Chiang Mai University

Background: Noninvasive prenatal diagnosis based on detection of fetal cell-free DNA is hampered when mother and father are both carriers for the same autosomal recessive mutation. Objective: To compare the diagnosis of Bart's hydrops fetalis using conventional Gap-PCR analysis of fetal cells/tissues with the measurement of quantitative difference (ΔCT) between α-thalassemia-1 SEA type deletion gene (CT-mutant) and wild type α-globin gene (CT-wild type) in plasma of pregnancies by using the Taqman real-time quantitative PCR. Material and Method: Plasma DNA samples were collected from three groups of pregnancies whose fetuses have known thalasemia status (7 normal, 11 heterozygote α-thalassemia-1 SEA type deletion, and 7 Bart's hydrops fetalis). The α-thalassemia-1 SEA type deletion gene and wild type α-globin gene were quantified by using Taqman real-time quantitative PCR and then the ΔCT was analyzed by subtracting the CT-mutant from CT-wild type. Results: Mean ΔCT values were not significantly different among the three groups. However, women whose fetuses were diagnosed as Bart's hydrops fetalis had a higher proportion (43%) of plasma DNA samples that had negative ΔCT value than women whose fetuses were diagnosed as normal or heterozygote α-thalassemia-1 SEA type deletion (0 and 27%, respectively). Conclusion: Further investigations are needed to improve the diagnosis of Bart's hydrops fetalis using fetal cell-free DNA.